Lytgobi
Term · Oncology and biomedicine · MLC-T-ONC-005061
A drug used to treat adults with intrahepatic cholangiocarcinoma (a type of cancer that forms in the bile ducts inside the liver) that has spread or cannot be removed by surgery and has an FGFR2 gene fusion or other change in the structure of the FGFR2 gene. It is used in patients whose cancer has already been treated. It is also being studied in the treatment of other types of cancer. Lytgobi blocks a protein called FGFR, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called futibatinib.
| Identifier | MLC-T-ONC-005061 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | futibatinib |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-005061",
"term": "Lytgobi",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat adults with intrahepatic cholangiocarcinoma (a type of cancer that forms in the bile ducts inside the liver) that has spread or cannot be removed by surgery and has an FGFR2 gene fusion or other change in the structure of the FGFR2 gene. It is used in patients whose cancer has already been treated. It is also being studied in the treatment of other types of cancer. Lytgobi blocks a protein called FGFR, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called futibatinib.",
"synonyms": [
"futibatinib"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/lytgobi/"
}
Record 10,505 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.